FTC (US Federal Trade Commission) approves AmeriPath sale, shareholders rebel:
This article was originally published in Clinica
Executive Summary
The US Federal Trade Commission has given antitrust clearance to the acquisition of genomic and cancer diagnostic services group AmeriPath by buy-out firm Welsh Carson Anderson & Stowe. WCAS unit Amy Acquisition is offering $21.25 per share in cash and to assume $172m of debt. Shareholders with a combined stake of about 4.5% have filed a lawsuit against the firm's directors on the grounds that the price is too low and not in shareholders' interests. AmeriPath's share is currently trading at $21.60; it was selling for $16.45 immediately before the offer was made in December.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.